ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT02325557 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Prostate Cancer

Interventions

DRUG: ADXS31-142
DRUG: Pembrolizumab

Sponsor

Advaxis, Inc.

Collaborators

[object Object]